2
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Withdrawn
1
Unknown
1
Terminated
1
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Classical hematology
1
Conditions
Hematologic Neoplasms
1
Febrile Neutropenia
1
Interventions
Cyclophosphamide
129
Cisplatin
119
Radiotherapy
115
pembrolizumab
111
Carboplatin
97
Paclitaxel
96
Gemcitabine
96
Magnetic Resonance Spectroscopy
80
Nivolumab
76
Bevacizumab
76
Fluorouracil
74
Dexamethasone
73
Radiosurgery
66
Docetaxel
59
Rituximab
58
Leucovorin
57
Oxaliplatin
55
Capecitabine
55
Biopsy
53
Doxorubicin
52
fludarabine
51
Drug Therapy
45
durvalumab
44
Cytarabine
44
Etoposide
42
fludarabine phosphate
40
Pemetrexed
40
Radiation
39
atezolizumab
36
Surveys and Questionnaires
36
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Withdrawn
×
ceftolozane, tazobactam drug combination
×
Clear all
NCT05061654
2023-08-14
CEF-10
Hamad Medical Corporation
Phase 4
Withdrawn